Indoco Remedies Limited INDOCO NSEPHARMA
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. Additionally, it provides contract research services, such as custom chemical synthesis of molecules and intermediates; process chemistry research and development; non-infringing process designing and scale up; and analytical method development, validation, impurity characterization, and polymorphic studies, solutions, as well as intellectual property management. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -55.6% CAGR over 5 years.
- Trading 38.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INDOCO Indoco Remedies Limited NSEPHARMA | 209.66 | - | ₹1,932.51 Cr | 0.10% | 1.02% | -10.12% | 3.02% | -55.63% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 383.89 Cr | 429.08 Cr | 471.83 Cr | 434.34 Cr | 455.90 Cr |
| Cost of Revenue | 105.97 Cr | 134.97 Cr | 145.34 Cr | 120.42 Cr | 141.01 Cr |
| Gross Profit | 277.92 Cr | 294.11 Cr | 326.49 Cr | 313.92 Cr | 314.89 Cr |
| Operating Expenses | 307.48 Cr | 306.28 Cr | 315.69 Cr | 314.42 Cr | 297.67 Cr |
| Operating Income | -29.56 Cr | -12.17 Cr | 10.80 Cr | -50.00 L | 17.22 Cr |
| EBITDA | 1.24 Cr | 19.16 Cr | 43.28 Cr | 26.34 Cr | 53.41 Cr |
| Interest Expense | 17.98 Cr | 26.12 Cr | 24.56 Cr | 25.64 Cr | 45.92 Cr |
| Pretax Income | -45.52 Cr | -36.66 Cr | -13.53 Cr | -31.31 Cr | -25.00 Cr |
| Tax Provision | -4.18 Cr | -31.00 L | -4.32 Cr | -1.86 Cr | -1.32 Cr |
| Net Income | -40.39 Cr | -35.79 Cr | -7.93 Cr | -29.79 Cr | -21.64 Cr |
| Diluted EPS | -4.48 | -3.94 | -1.00 | -3.20 | -2.57 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 1,640.05 Cr | 1,788.22 Cr | 1,641.29 Cr | 1,792.94 Cr |
| Cost of Revenue | - | 539.31 Cr | 582.10 Cr | 498.18 Cr | 541.74 Cr |
| Gross Profit | - | 1,100.73 Cr | 1,206.12 Cr | 1,143.11 Cr | 1,251.20 Cr |
| Operating Expenses | - | 903.10 Cr | 1,063.26 Cr | 1,157.69 Cr | 1,235.85 Cr |
| Operating Income | - | 197.64 Cr | 142.86 Cr | -14.58 Cr | 15.35 Cr |
| EBITDA | - | 287.15 Cr | 262.59 Cr | 105.70 Cr | 142.19 Cr |
| Interest Expense | - | 23.75 Cr | 34.93 Cr | 66.23 Cr | 122.25 Cr |
| Pretax Income | - | 192.79 Cr | 135.80 Cr | -74.37 Cr | -106.51 Cr |
| Tax Provision | - | 50.54 Cr | 38.79 Cr | 3.58 Cr | -7.81 Cr |
| Net Income | - | 142.25 Cr | 98.46 Cr | -73.74 Cr | -95.15 Cr |
| Diluted EPS | 16.80 | 15.42 | 10.67 | -8.46 | - |
Compounded Sales Growth
| 5 Years: | 3.02% |
| 1 Year: | 21.90% |
Compounded Profit Growth
| 5 Years: | -55.63% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -17.17% |
| 6 Months: | -17.06% |
| 3 Months: | +4.93% |
| 1 Month: | +0.07% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 1,658.20 Cr | 2,144.73 Cr | 2,429.91 Cr | 2,593.27 Cr |
| Current Assets | - | 813.57 Cr | 954.67 Cr | 1,001.34 Cr | 1,193.35 Cr |
| Cash & Equivalents | - | 10.92 Cr | 14.86 Cr | 12.10 Cr | 25.93 Cr |
| Inventory | - | 325.99 Cr | 353.06 Cr | 419.35 Cr | 405.21 Cr |
| Receivables | - | 350.94 Cr | 406.20 Cr | 352.41 Cr | 489.17 Cr |
| Total Liabilities | - | 629.95 Cr | 1,034.23 Cr | 1,411.54 Cr | 1,661.16 Cr |
| Current Liabilities | - | 424.51 Cr | 612.33 Cr | 807.99 Cr | 1,052.54 Cr |
| Long Term Debt | - | 143.50 Cr | 351.73 Cr | 533.20 Cr | 516.02 Cr |
| Total Debt | - | 332.85 Cr | 671.95 Cr | 993.57 Cr | 1,089.75 Cr |
| Total Equity | - | 1,028.25 Cr | 1,109.90 Cr | 1,022.00 Cr | 939.28 Cr |
| Shares Outstanding | - | 9.22 Cr | 9.22 Cr | 9.22 Cr | 9.23 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 178.83 Cr | 155.39 Cr | 90.76 Cr | 226.35 Cr |
| Investing Cash Flow | - | -208.17 Cr | -432.52 Cr | -259.79 Cr | -87.38 Cr |
| Financing Cash Flow | - | 22.80 Cr | 280.43 Cr | 168.62 Cr | -133.09 Cr |
| Capital Expenditure | - | -207.25 Cr | -425.99 Cr | -258.43 Cr | -125.35 Cr |
| Free Cash Flow | - | -28.42 Cr | -270.60 Cr | -167.67 Cr | 101.00 Cr |
| Net Change in Cash | - | -6.54 Cr | 3.31 Cr | -41.00 L | 5.88 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 67.1% | 67.4% | 69.6% | 69.8% |
| Operating Margin % | - | 12.1% | 8.0% | -0.9% | 0.9% |
| Net Margin % | - | 8.7% | 5.5% | -4.5% | -5.3% |
| ROE % | - | 13.8% | 8.9% | -7.2% | -10.1% |
| ROCE % | - | 16.0% | 9.3% | -0.9% | 1.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INDOCO